Congress reports

Congress reports

Each memo inOncology SPECIAL ISSUE congress report delivers the latest in lung cancer research to come out of a major international oncology congress. Each issue is now translated into Chinese (Mandarin), Spanish, and Japanese. The next SPECIAL ISSUE report will summarise findings presented at the Annual Congress of the American Society of Clinical Oncology (ASCO), June 2018.

Access Congress Reports here:

WCLC 2018

Expert interviews at WCLC 2018


Herbert Loong on peculiarities of lung cancer research with a focus on phase I studies.

James Ho talks about novel diagnostic approaches, monitoring of lung cancer patients as well as the potential for the use of antioxidants in lung cancer.

Maximilian Hochmair on the future of combinations of immunotherapies with other drugs as well as his recommendations for treatment sequencing in ALK-positive and EGFR-positive lung cancer.

Vera Hirsh discusses the latest clinical achievements using EGFR-targeted therapy in patients with advanced NSCLC and the role of patient quality of life.

Virote Sriuranpong talks about new agents in the area of EGFR-targeted therapy as well as the results obtained with afatinib in a named patient program at Asian centers.

ASCO 2018

Expert interviews at ASCO 2018


Edward Kim talks about the relevance of biomarkers in choosing patients for immunotherapy and the usefulness/pitfalls pf liquid biopsies.

Barbara Melosky talks about ongoing trials that evaluate afatinib/pembrolizumab combination therapy of squamous-cell carcinoma and potential combinations of anti-EGFR agents with anti-angiogenesis drugs.

Terufumi Kato talks about the nationwide screening project LC-SCRUM-Japan and the insights that have been obtained through these data in general and regarding squamous-cell lung cancer in particular.

WCLC 2017

Expert interviews at WCLC

IASLC 18th WCLC 2017, Yokohama
Prof. David Gandara discusses the latest progress in EGFR, ALK, and checkpoint inhibitor therapies for NSCLC.

IASLC 18th WCLC 2017, Yokohama
Prof. Keunchil Park discusses how lung cancer treatments have developed since the advent of chemotherapy, and how best to deliver optimal care to lung cancer patients worldwide, and specifically in South Korea and Japan.

IASLC 18th WCLC 2017, Yokohama
Prof. Ramaswamy Govindan discusses the importance of chemotherapy in today’s treatment landscape, and the importance of ethnic genomic differences in mutation rates in lung cancer.

IASLC 18th WCLC 2017, Yokohama
Prof. Paul A. Bunn discusses current and future treatment options in lung cancer.

ESMO 2017

Expert interviews at ESMO


Hossein Borghaei discusses the latest immunotherapeutic treatment options to emerge for lung cancer at the 2017 ESMO congress.

Nicolas Girard on the sequencing of targeted agents against EGFR positive NSCLC, and further considerations for treatment of the disease including side effects and possible combination therapies.

Lecia Sequist on how best to treat oncogene-driven oligometastatic lung cancer, given progression through multiple lines of treatment.

Filippo de Marinis on the latest data from the OAK trial studying the PD-L1 antibody atezolizumab that was presented at the 2017 ESMO congress, including efficacy within particular patient subgroups, and tolerability.

ASCO 2017

Expert interviews at ASCO

Richard Baird on clinical trial data for treatment of cerebral metastases, including the Cambridge brain mets trial 1 (CamBMT1) phase 1B trial data that he presented at ASCO.

Anna Nowak on malignant mesothelioma: risk factors, prognostic markers, and clinical trial data for mesothelioma treatments to come out of the congress.

Yi-Long Wu, president of the Chinese Society of Clinical Oncology, discusses his society’s collaboration with memo inOncology, and the approval of afatinib for EGFR+ NSCLC in China.

Maya Gottfried on NSCLC screening and treatment options

WCLC 2016

Expert interviews at WCLC

Martin Schuler on the current state-of-play for EGFR diagnostic technologies

Johan Vansteenkiste discusses the practical considerations for immunotherapy

Robert Pirker on the hot topics in lung cancer research on the agenda at the IASLC 2017 WCLC congress

Fiona Blackhall on the importance of molecular diagnosis on the diagnosis and follow up of lung cancer

James Chih-Hsin Yang talks TKIs